INmune Bio (INMB) Announces Approximately $19 Million Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
BTIG Downgrades INmune Bio Inc. (INMB) to Neutral
June 30, 2025 4:37 PM EDTBTIG analyst Thomas Shrader downgraded INmune Bio Inc. (NASDAQ: INMB) from Buy to Neutral.
The analyst comments "A solid MAYBE but with no clear way forward and management talking about moving to other programs - so NEUTRAL makes sense. The size of the AD opportunity hasn't changed, so the current stock price (about $2 all day) equates to a probability of success in AD of 0% with all revenues coming from MDD. Our two biggest worries going into this readout (preview HERE) were: 1) the modest enrichment in the MINDFul trial population, based on one (of four)... More
